局部进展期直肠癌新辅助治疗--精准医疗时代的思考  

Neoadjuvant chemotherapy of locally advanced rectal cancer :thinking of the precise treatment era

作　　者：杨立峰[1] 章真[1] 

机构地区：[1]复旦大学附属肿瘤医院放疗科,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《南京医科大学学报（自然科学版）》2016年第3期264-268,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：国家自然科学基金(81372432,81572955)

摘　　要：术前新辅助放化疗已成为局部晚期直肠癌的标准治疗方案,目前的研究热点集中在如何预测新辅助治疗的疗效,富集优势人群,避免不敏感患者的过度治疗,减少不必要的医疗开支。近两年随着基因测序技术的迅速发展,依据基因表达对结直肠癌进行分子分型并判断患者的药物敏感性及预后,对于不同基因表达的患者给予个体化精准治疗成为目前治疗的重点,本文将对以上方面进行综述。Neoadjuvant chemotherapy has become the standard treatment for locally advanced rectal cancer. The focus of the research is to predict the efficacy of neoadjuvant therapy,to enrich the advantages of people and avoid the excessive treatment as well as reduce unnecessary medical expenses. In the past several years,with the rapid development of gene sequencing technology,based on the gene expression of colorectal cancer molecular subtype to predict patient＇s drug sensitivity and prognosis,individual patients with different gene type undergoing precise treatment has become the focus of the current treatment.

关 键 词：局部晚期直肠癌 新辅助放化疗 分子分型 精准治疗 

分 类 号：A735.3[哲学宗教—马克思主义哲学]